Type / Class
Equity / Common shares, Euro 0.12 nominal value per share
Shares outstanding
26.3M
Number of holders
17
Total 13F shares, excl. options
7.37M
Shares change
-86.7K
Total reported value, excl. options
$25.8M
Value change
-$426K
Number of buys
9
Number of sells
-5
Price
$3.50

Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q4 2022

19 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q4 2022.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.37M shares of 26.3M outstanding shares and own 27.99% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (3.33M shares), Redmile Group, LLC (2.82M shares), SILVERARC CAPITAL MANAGEMENT, LLC (438K shares), AXA S.A. (227K shares), Artal Group S.A. (200K shares), Alpha Wave Global, LP (120K shares), Bruce & Co., Inc. (100K shares), PNC Financial Services Group, Inc. (50K shares), Kapitalo Investimentos Ltda (21.2K shares), and RENAISSANCE TECHNOLOGIES LLC (18.8K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.